Coverage of Geron kicks off at BTIG with a Buy rating

BTIG analyst Thomas Shrader suggests the stock has been 'left for dead' unfairly

Buy and hold
The biotech's flagship drug is Imetelstat – a telomerase inhibitor active in the treatment of myelodyspastic syndrome, a bone marrow disorder

Shares of Geron Corp (NASDAQ:GERN) are soaring after BTIG analyst Thomas Shrader initiated coverage of the biotech with a Buy rating and a price target of $4.00.

Shrader says the stock has been “left for dead” unfairly, despite trials of its flagship drug “Imetelstat – a telomerase inhibitor active in the treatment of highly transfusion-dependent myelodyspastic syndrome, and r/r myelofibrosis", two bone marrow disorders, showing clear indications of efficacy.

READ: Geron shares tumble after Janssen Biotech ends collaboration on imetelstat drug program

The drug had been the subject of a partnership with Johnson & Johnson (NYSE:JNJ), but Geron has now taken over sole ownership of its development, with pivotal trials starting this year.

“Geron is likely to attract investor interest as corroborative pivotal readouts approach,” Shrader wrote in a note to investors.

Geron shares traded 6.9% higher at $1.40 in morning trade on Wednesday.

Contact Ellen Kelleher at [email protected]

Quick facts: Geron

Price: 2.18 USD

Market: NASDAQ
Market Cap: $676.6 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Legend Mining's Mark Wilson hails best results to date at Mawson and updates...

Legend Mining Limited's (ASX:LEG) Mark Wilson tells Proactive's Andrew Scott they've hit their best result yet at Mawson from hole 18 - an intersection of 4.5 metres at 3.05% nickel, 2.32% copper and 0.19% cobalt the best grades to date. Wilson adds that they recently received strong support...

14 hours, 55 minutes ago

2 min read